Frey M

No ORCID on file · 1 paper in corpus

2013

p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer.

Journal of cancer research and clinical oncology ·doi:10.1007/s00432-013-1432-2

PurposeTo evaluate the use of p53-autoantibodies (p53-aab) for monitoring minimal disease after standard therapy of advanced epithelial ovarian cancer (EOC).MethodsRetrospective analysis of p53-aab in preoperative and long-term follow-up se…